4D Molecular Therapeutics Advances Clinical Programs in Q2 2025

4D Molecular Therapeutics, Inc. ( (FDMT) ) has released its Q2 earnings. Here is a breakdown of the information 4D Molecular Therapeutics, Inc. presented to its investors.

4D Molecular Therapeutics, Inc. is a biotechnology company focused on developing durable and disease-targeted therapeutics, particularly in the field of genetic medicine for retinal and pulmonary diseases. In its second quarter of 2025, 4DMT reported significant progress in its clinical programs, particularly with its lead product candidate, 4D-150, for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The company has accelerated its Phase 3 program for 4D-150 in wet AMD, with the 4FRONT-1 data readout moved up to the first half of 2027, and the initiation of 4FRONT-2 ahead of schedule. Additionally, positive 60-week results from the SPECTRA trial in DME were presented, showcasing favorable tolerability and sustained treatment effects.

Key financial highlights include a cash position of $417 million, expected to fund operations into 2028, despite a net loss of $54.7 million for the quarter. Research and development expenses rose to $48 million, largely due to the initiation of Phase 3 trials for 4D-150. The company also announced a workforce reduction to streamline operations, which is expected to save approximately $15 million annually.

Looking ahead, 4DMT is focused on completing its Phase 3 trials for 4D-150 and preparing for potential commercialization, with alignment from both the FDA and EMA on the approval pathway. The company is also advancing its pulmonology program with 4D-710 for cystic fibrosis, with interim data expected later in 2025. Overall, 4DMT is positioning itself for significant milestones in the coming years, with a strong emphasis on late-stage clinical execution.